Fibrocell Science (NASDAQ:FCSC) is up 64% premarket on light volume in reaction to its agreement to be acquired by collaboration partner Castle Creek Pharmaceutical Holdings for an undisclosed sum.
Both companies are developing therapies to treat a rare skin disorder called epidermolysis bullosa.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.